好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neurological Disorders associated with COVID-19 in Singapore
General Neurology
General Neurology Posters (7:00 AM-5:00 PM)
016

To describe the neurological disorders associated with COVID-19 in Singapore.

Various neurological disorders have been reported in COVID-19 patients. Postulated mechanisms include hypercoagulopathy, dysimmunity, inflammation and direct viral invasion. The incidence and relationship to SARS-CoV-2, considering the confounding effect of a surge in COVID-19 cases on healthcare systems, are unclear.

This was a prospective, nation-wide, multi-centre, cohort study of patients with microbiologically-confirmed COVID-19 referred for any neurological complaints within 3 months of infection. Neurological diagnoses and relationship to COVID-19 were made by consensus guided by contemporaneous published case definitions.

Between March-July 2020, 47,572 patients [median age 34 (1-102) years, 98% males] were diagnosed with COVID-19 in Singapore. Of 90 patients referred for neurological disorders, 39 [median age 41 (27-73) years, 97% males] were deemed related to COVID-19 and categorised as: i) Central nervous system syndromes - 3 encephalitis, 1 acute disseminated encephalomyelitis; ii) Cerebrovascular disorders - 19 acute ischemic stroke/transient ischemic attack (AIS/TIA), 4 cerebral venous thrombosis (CVT) and 2 intracerebral haemorrhage; iii) Peripheral nervous system - 7 mono/polyneuropathy;  iv) Autonomic nervous system - 4 limited dysautonomia. Fifty-one other patients had pre/co-existent neurological conditions (headache, seizure, mononeuropathies and functional neurological disorders) unrelated to COVID-19. Encephalitis is delayed, occurring in critical COVID-19, while CVT and dysautonomia occurred relatively early and largely in mild infections. AIS/TIA was variable in onset; remarkably 63.2% had asymptomatic COVID-19. CVT was more frequent than expected and occurred in patients with mild/asymptomatic COVID-19. The pathophysiology of COVID-19 neurology appeared to be dysimmunity and/or prothrombotic tendency. There were no neurological complications in all 81 paediatric COVID-19 cases.

COVID-19 neurology has a wide spectrum of dysimmune-thrombotic disorders. The relatively few cases recorded was probably because our outbreak affected mainly healthy young men with mild/asymptomatic COVID-19 and the pandemic did not unduly affect the Singapore healthcare system.

Authors/Disclosures
Rebecca Hoe, MBBS, MRCP (National Neuroscience Institute)
PRESENTER
Dr. Hoe has nothing to disclose.
Jasmine Koh, MBBS (Tan Tock Seng Hospital) Dr. Koh has nothing to disclose.
No disclosure on file
No disclosure on file
Hui Jin Chiew, MBBS (National Neuroscience Institute) Dr. Chiew has nothing to disclose.
Tian Ming Tu, MD (Neurology Care Partners) Dr. Tu has nothing to disclose.
Christopher Seet, MBBS (National Neuroscience Institute) Dr. Seet has nothing to disclose.
No disclosure on file
Andrew C. Hui, MBBS, FRCP (Medicine) Dr. Hui has nothing to disclose.
No disclosure on file
No disclosure on file
Ming Hui Yong, MD (National Neuroscience Institute, Singapore General Hospital) Dr. Yong has nothing to disclose.
Yihui Goh, MBBS (National University Hospital) Dr. Goh has nothing to disclose.
No disclosure on file
No disclosure on file
Benjamin Yong Qiang Tan Benjamin Yong Qiang Tan has nothing to disclose.
Wei Ping Kay Ng, MD (National University Hospital) Dr. Ng has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Astra Zeneca.
Leonard L. Yeo, MBBS (NUHS) The institution of Dr. Yeo has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Astrazeneca. The institution of Dr. Yeo has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for stryker. Dr. Yeo has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for NUHS. Dr. Yeo has received stock or an ownership interest from cereflo. The institution of Dr. Yeo has received research support from NMRC.
No disclosure on file
Prakash Kumar, MD (National Neuroscience Institute) No disclosure on file
Aftab Ahmad, MD (Jurong Health Services Singapore) Dr. Ahmad has nothing to disclose.
No disclosure on file
No disclosure on file
Kevin Tan, MD, FAAN (National Neuroscience Institute) Dr. Tan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Tan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Tan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck.
No disclosure on file